JULIO
ARRIZABALAGA AGUIRREAZALDEGUI
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublications in collaboration with researchers from Hospital de la Santa Creu i Sant Pau (9)
2017
2016
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
2015
-
Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5
2011
-
Restoration of T cell responses to Toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis
Clinical Infectious Diseases, Vol. 52, Núm. 5, pp. 662-670
2010
-
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: Three-year results (The Advanz Trial): A randomized, controlled trial
AIDS Research and Human Retroviruses, Vol. 26, Núm. 7, pp. 747-757
2009
-
(Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))
Enfermedades Infecciosas y Microbiologia Clinica
2005
2000
-
Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: The Scan Study
AIDS, Vol. 14, Núm. 16, pp. 2485-2494